Skyline, Clavis collaborate in Leukemia research
The Dutch biotech company Skyline Diagnostics and the Norwegian drug development company Clavis Pharma have signed a research agreement. Under this agreement, Skyline will investigate gene expression biomarkers for selection of individual Acute Myeloid Leukemia (AML) patients that may benefit from a new AML drug in development at Clavis. This drug, elacytarabine, is a novel elaidic acid derivative of cytarabine and currently undergoing the CLAVELA phase III study for treatment of patients with relapsed/refractory AML.
Athos Gianella-Borradori, CMO of Clavis Pharma said, "This genomic approach adds to our currently ongoing patient selection based on protein markers and will deepen our insights into the potential for precise and highly effective personalized medicines. It is our goal and vision that this collaboration with the experts of Skyline will bring better therapies to the many patients suffering from difficult-to-treat leukemia."